Australia Markets closed
  • ALL ORDS

    7,490.10
    -178.80 (-2.33%)
     
  • AUD/USD

    0.7187
    -0.0041 (-0.5620%)
     
  • ASX 200

    7,175.80
    -166.60 (-2.27%)
     
  • OIL

    0 (0)
     
  • GOLD

    1,841.10
    -0.60 (-0.03%)
     
  • BTC-AUD

    50,571.30
    +1,026.52 (+2.07%)
     
  • CMC Crypto 200

    823.79
    +13.18 (+1.63%)
     

Integrity Applications Announces Uplisting to Nasdaq Capital Market

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • IGAP

Wilmington, DE and Or Yehuda, Israel, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Integrity Applications, Inc. (www.integrity-app.com) (OTCQB: IGAP), innovator of GlucoTrack®, a non-invasive device for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today that its shares of common stock were approved for listing on the Nasdaq Capital Market.

Trading on Nasdaq is expected to commence on Friday, December 10, 2021 under its existing trading symbol, IGAP. The Company intends to file an application with Nasdaq to effect the previously announced name change to GlucoTrack, Inc. and related change in ticker symbol post the uplisting.

"We are thrilled to announce the listing of our shares on Nasdaq, representing a significant milestone for the Company and its shareholders," said Paul V. Goode, President and Chief Operating Officer. " As we continue to make significant progress towards bringing GlucoTrack to market, we believe that the listing will help increase corporate visibility, provide investors with increased liquidity, and enhance shareholder value."

About GlucoTrack®

GlucoTrack® is a truly non-invasive monitoring device that rapidly measures and displays an individual’s glucose level in about a minute without finger pricking or any pain. GlucoTrack® features an ear clip with sensors that clips to the earlobe and measures the user’s glucose level using innovative and patented sensor technologies. The measured signals are analyzed using a proprietary algorithm and then a calculated glucose level is displayed on a small handheld device the size of a small mobile phone. The glucose results are stored in the device and used to estimate HbA1c level using a proprietary algorithm. The device can also display glucose values graphically, enabling the user to monitor glucose levels over time.

About Integrity Applications, Inc.

Integrity Applications, Inc. (OTCQB: IGAP) was founded in 2001 and is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies for people with type 2 diabetes and prediabetes. The Company has developed GlucoTrack®, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements in about a minute without the pain, incremental cost, difficulty, or discomfort of conventional invasive finger stick devices. Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel. For more information, please visit http://www.integrity-app.com/ and http://www.glucotrack.com.

Investor Contact: investors@integrity-app.com
Media Contact: media@integrity-app.com

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “expect”, “plan” and “will” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications’ actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications’ results include, but are not limited to, the ability of Integrity Applications to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to its current and future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Integrity Applications’ filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the SEC on April 13, 2021.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting